Poolbeg Pharma to present POLB 001 data at International Congress of Immunology in Cape Town
( ) , a clinical-stage biopharma company focused on infectious diseases, said it will present data related to its flagship POLB 001 anti-inflammatory candidate at the 18th International Congress of Immunology (IUIS), to be held 27 November - 2 December 2023 in Cape Town.
Poolbeg's presentation will focus on POLB 001's potential to treat hyperinflammation associated with cytokine release syndrome (CRS) that affects patients receiving CAR T-cell cancer therapies. CRS is an often encountered side effect of such immunotherapies that causes potentially life-threatening hyperinflammation. CRS is also associated with severe influenza.
Specifically, Poolbeg will provide insight into results obtained from the POLB 001 LPS human challenge trial, highlighting its potential use in the treatment of CRS.
The presentation will take place on December 1st, between 12 PM and 1 PM SAST under the title "Inhibition of local and systemic inflammatory responses by POLB 001, a novel p38 MAPK inhibitor, following in vivo LPS administration in healthy volunteers"
View from Vox
The acceptance of Poolbeg's abstract on POLB 001 at IUIS represents further validation of the candidate's potential in addressing CRS in oncology. IUIS is the world's leading immunology conference, attracting professionals and leaders from academia, healthcare companies, and independent research organisations among others, to share the latest advancements in immunological research.
Poolbeg's presentation in Cape Town will be followed a week later by a similar presentation at the American Society of Hematology Annual Meeting in San Diego, which is the world's leading conference on blood cancers.
CRS is highly prevalent among patients receiving immunotherapy for hematological malignancies. Mild to moderate cases of CRS require hospitalisation and can impact the ability to deliver the cancer immunotherapies while severe cases can become life-threatening and require intensive care.
An effective drug for CRS has the potential to make cancer immunotherapies more tolerable and accessible and enable patients to get the most benefit from their treatment. Positive results from the POLB 001 LPS challenge trial highlighted that oral treatment of POLB 001 holds substantial promise in tackling the issue of hyperinflammation associated with CRS.
Follow News & Updates from Poolbeg Pharma:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.